Oyster Point Pharma, Inc. was delisted on Jan 3, 2023; its insiders filed their last Form 4 on Jan 5, 2023; 53 institutions reported holding it in 13F filings for Q4 2022, worth $189.4M in total; no superinvestor held it.
SEC filings
10-K, 10-Q, 8-K, 20-F and 40-F reports Oyster Point Pharma, Inc. filed with the SEC, newest first.
Livermore lists each filing's form, 8-K items and dates only. To read a filing, open it on SEC.gov; an 8-K's press release or other attachments, such as exhibit 99.1 for Item 2.02, are in the filing index.
SEC filings by Oyster Point Pharma, Inc.
Filed
Form
8-K items
Period
Document
Filing index
Jan 13, 2023
8-K/AAmended current report
1.02Item 1.02: Termination of a material definitive agreement2.01Item 2.01: Completion of an acquisition or disposition of assets3.01Item 3.01: Notice of delisting or failure to meet a listing rule; transfer of listing3.03Item 3.03: Material modification to the rights of security holders5.01Item 5.01: Change in control of the company5.02Item 5.02: Departure or appointment of directors or officers; executive pay arrangements5.03Item 5.03: Amendment to the articles of incorporation or bylaws; change in fiscal year9.01Item 9.01: Financial statements and exhibits
1.02Item 1.02: Termination of a material definitive agreement2.01Item 2.01: Completion of an acquisition or disposition of assets3.01Item 3.01: Notice of delisting or failure to meet a listing rule; transfer of listing3.03Item 3.03: Material modification to the rights of security holders5.01Item 5.01: Change in control of the company5.02Item 5.02: Departure or appointment of directors or officers; executive pay arrangements5.03Item 5.03: Amendment to the articles of incorporation or bylaws; change in fiscal year9.01Item 9.01: Financial statements and exhibits
2.05Item 2.05: Costs of exit or disposal activities (restructuring)5.02Item 5.02: Departure or appointment of directors or officers; executive pay arrangements8.01Item 8.01: Other events9.01Item 9.01: Financial statements and exhibits
2.02Item 2.02: Results of operations and financial condition (earnings release)2.04Item 2.04: Event that accelerates or increases a financial obligation9.01Item 9.01: Financial statements and exhibits